B. Adams, A. Chan, H. Callahan, and N. W. Milgram, The canine as a model of human cognitive aging: Recent developments, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.24, issue.5, pp.675-692, 2000.
DOI : 10.1016/S0278-5846(00)00101-9

P. Adlard, R. Cherny, D. Finkelstein, E. Gautier, and E. Robb, Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A??, Neuron, vol.59, issue.1, pp.43-55, 2008.
DOI : 10.1016/j.neuron.2008.06.018

M. Ahmed, H. Hoshino, and T. Chikuma, Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model ? Neuroscience, pp.639-688, 2004.

G. E. Alexander, K. Chen, P. Pietrini, S. I. Rapoport, and E. Reiman, Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer???s Disease Treatment Studies, American Journal of Psychiatry, vol.159, issue.5, pp.738-783, 2002.
DOI : 10.1176/appi.ajp.159.5.738

G. Arendash, M. Gordon, and D. Diamond, Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory -DNA and cell biology, pp.737-781, 2001.

E. Arias, S. Gallego-sandín, and M. Villarroya, Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors, Journal of Pharmacology and Experimental Therapeutics, vol.315, issue.3, pp.1346-53, 2005.
DOI : 10.1124/jpet.105.090365

A. Nationale, une approche historique -Découvertes scientifiques, évolutions de la société, travaux législatifs, 2000.

S. Avet, La prise en soins d'un patient atteint de la maladie d'Alzheimer, au travers de situations spécifiques -NPG Neurologie, 2008.
DOI : 10.1016/j.npg.2008.01.002

S. Bakchine and M. Habert, -Classification des démences : aspects nosologiques -Médecine Nucléaire, Juin, vol.31, issue.6, pp.278-293, 2007.
DOI : 10.1016/j.mednuc.2007.04.005

E. Baldi, M. Efoudebe, C. Lorenzini, and C. Bucherelli, -Spatial navigation in the Morris water maze: working and long lasting reference memories -Neuroscience Letters, pp.176-80, 2005.

W. Banks, Drug delivery to the brain in Alzheimer's disease: Consideration of the blood?brain barrier -Advanced Drug Delivery Reviews, pp.629-639, 2012.

P. Barberger-gateau, L. Letenneur, P. Kfr, and /. , -Résultats de l'étude Paquid 2004 -www.isped.u- bordeaux2, 2012.

F. Bard, C. Cannon, and R. Barbour, Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, vol.6, issue.8, pp.916-935, 2000.
DOI : 10.1038/78682

R. Bateman and W. Klunk, -Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease ? Neurotherapeutics, pp.381-90, 2008.

R. Bateman, T. Benzinger, and N. Cairns, Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) -Alzheimer's & Dementia, p.4, 2012.

R. Bateman, C. Xiong, and T. Benzinger, Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012.
DOI : 10.1056/NEJMoa1202753

M. Beydoun, H. Beydoun, and Y. Wang, Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis, Obesity Reviews, vol.42, issue.3, pp.204-218, 2008.
DOI : 10.1212/WNL.42.3.473

J. Birks, Cholinesterase inhibitors for Alzheimer's disease -The Cockrane Library, 2006.

N. Bons, F. Rieger, and D. Prudhomme, Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?, Genes, Brain and Behavior, vol.32, issue.2, pp.120-130, 2006.
DOI : 10.1016/S0197-4580(89)80005-3

R. Bordet, Alzheimer : au-delà de la seule hypothèse cholinergique -Autres systèmes de neurotransmission et modulation des récepteurs nicotiniques -La Lettre du Pharmacologue, 2003.

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.839-859, 1991.
DOI : 10.1007/978-3-642-70644-8_2

G. Braillon, -Le système nerveux central -Editions Pradel, 2002.

R. Brinton, Impact of Estrogen Therapy on Alzheimer??s Disease, CNS Drugs, vol.2, issue.4, pp.405-427, 2004.
DOI : 10.2165/00023210-200418070-00001

T. Buckley and C. Corcoran, NSAID use does not affect dementia progression or survival in Alzheimer's disease. The Cache County Dementia Progression Study., Alzheimer's & Dementia, vol.7, issue.4, p.367, 2011.
DOI : 10.1016/j.jalz.2011.05.1056

M. Carrillo, H. Brashear, and V. Logovinsky, Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease -Alzheimers Dement, pp.123-131, 2013.

P. Couraud, -La barrière hémato-encéphalique -Médecine thérapeutique, pp.285-92, 2002.

P. Charazac, Soigner la maladie d'Alzheimer: Guidance des aidants et relation soignante -Dunod, 2012.

J. Chatard, Sport et santé: Quelle activité physique pour quelle santé ?-Université de Saint-Etienne, 2005.

F. Checler and L. Buée, -Données fondamentales sur les pathologies amyloïde et Tau dans la maladie d'Alzheimer: quelles perspectives thérapeutiques? -Annales Pharmaceutiques Françaises, pp.136-153, 2009.
DOI : 10.1016/j.pharma.2009.01.002

C. Clark, L. Sheppard, G. Fillenbaum, D. Galasko, J. Morris et al., Variability in Annual Mini-Mental State Examination Score in Patients With Probable Alzheimer Disease, Archives of Neurology, vol.56, issue.7, pp.857-62, 1999.
DOI : 10.1001/archneur.56.7.857

B. Croisile, -Tout sur la mémoire -Editions Odile Jacob, 2009.

B. Croisile, -La maladie d'Alzheimer ? Identifier Comprendre Accompagner -Editions Larousse, 2010.

J. Cummings, Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials -Alzheimer's & Dementia, pp.263-271, 2006.

A. Delacourte, -Revue Maladie d'Alzheimer : Physiopathologie, Médecine thérapeutique, 1997.

D. Wouters and N. , Ateliers d'art-thérapie: une nouvelle approche pour les personnes atteintes de la maladie d'Alzheimer et troubles apparentés -Oplinter Kluwer, 2007.

D. Dickson, J. Farlo, and P. Davies, Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques, American Journal of Pathology, vol.132, issue.1, pp.86-101, 1988.

R. Doody, P. Massman, and J. Dunn, -A method for estimating progression rates in Alzheimer's disease, Archives of Neurology, vol.58, pp.449-54, 2001.

R. Doody, R. Raman, and M. Farlow, A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease, New England Journal of Medicine, vol.369, issue.4, pp.341-350, 2013.
DOI : 10.1056/NEJMoa1210951

B. Dubois, H. Feldman, and C. Jacova, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007.
DOI : 10.1016/S1474-4422(07)70178-3

B. Dubois, H. Feldman, C. Jacova, J. Cummings, and S. Dekosky, Revising the definition of Alzheimer's disease: a new lexicon, The Lancet Neurology, vol.9, issue.11, pp.1118-1145, 2010.
DOI : 10.1016/S1474-4422(10)70223-4

K. Duff and F. Suleman, -Transgenic mouse models of Alzheimer?s disease: how useful have they been for therapeutic development?, Genomics Proteomics, vol.3, pp.47-59, 2004.

R. Epis, F. Gardoni, and E. Marcello, Searching for new animal models of Alzheimer's disease - European Journal of Pharmacology, pp.57-63, 2010.

A. Ergis and E. Eusop-roussel, -Les troubles précoces de la mémoire épisodique dans la maladie d'Alzheimer -Revue Neurologique, pp.96-101, 2008.

A. Ergis, Xe Colloque international sur le vieillissement cognitif: 4-5 septembre, 2008.

F. Eustache, Alzheimer et démences La maladie d'Alzheimer et la mémoire humaine - Revue Neurologique, pp.929-939, 2006.
DOI : 10.1016/s0035-3787(06)75102-5

R. Etcheberrigaray, M. Tan, and I. Dewachter, Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice, Proceedings of the National Academy of Sciences, pp.1141-1187, 2004.
DOI : 10.1001/archpsyc.57.1.95

M. Etminan, S. Gill, and A. Samii, The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies, Pharmacotherapy, vol.59, issue.6, pp.726-756, 2003.
DOI : 10.1016/S0025-7125(02)00008-1

H. Fagherazzi, -Projet ETNA3 : évaluer trois thérapeutiques non médicamenteuses dans la maladie d'Alzheimer -Chronisanté, 2012.

P. Faller and C. Hureau, -Le rôle des ions métalliques dans la maladie d'Alzeimer : apport de la spectroscopie d'absorption X -L'actualité chimique, pp.356-357, 2011.

M. Farlow, S. Arnold, and C. Van-dyck, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease -Alzheimers Dement, pp.261-71, 2012.

S. Faure, Médicaments de l'Alzheimer -Actualités Pharmaceutiques, pp.43-46, 2008.

A. Feigin, -Evidence from biomarkers and surrogate endpoints ? NeuroRx, pp.323-353, 2004.
DOI : 10.1007/bf03206617

URL : http://europepmc.org/articles/pmc534933?pdf=render

H. Feldman, R. Doody, and M. Kivipelto, Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe, Neurology, vol.74, issue.12, pp.956-64, 2010.
DOI : 10.1212/WNL.0b013e3181d6476a

F. Ferreri, C. Agbokou, and S. Gauthier, -Effets cardio-vasculaires des inhibiteurs de la cholinestérase dans la maladie d'Alzheimer -Revue Neurologique, pp.968-974, 2007.
DOI : 10.1016/s0035-3787(07)92641-7

C. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni et al., Global prevalence of dementia, Alzheimer's & Dementia, vol.5, issue.4, pp.2112-2119, 2005.
DOI : 10.1016/j.jalz.2009.05.374

F. Forette and A. Eveillard, -Mieux vivre avec la Maladie d'Alzheimer -Hachette Pratique, 2005.

F. Forette and J. Hauw, -Traitement symptomatique de la maladie d'Alzheimer et perspectives thérapeutiques ? Thérapie, 2010.
DOI : 10.2515/therapie/2010055

M. Fortin, Krolak-Salmon P. -Maladie d'Alzheimer et maladies apparentées : vers un diagnostic plus précis et précoce -La Revue de Médecine Interne, pp.846-853, 2010.

M. Fouquet, N. Villain, and G. Chételat, Imagerie cérébrale et physiopathologie de la maladie d'Alzheimer -Psychologie & NeuroPsychiatrie du vieillissement, pp.269-79, 2007.

A. Fradagrada and G. Furelaud, -Biologie cellulaire UE2 PACES: Manuel, cours + QCM corrigés - Ediscience, 2012.

L. Fratiglioni, S. Paillard-borg, and B. Winblad, An active and socially integrated lifestyle in late life might protect against dementia, The Lancet Neurology, vol.3, issue.6, pp.343-53, 2004.
DOI : 10.1016/S1474-4422(04)00767-7

W. Froestl, M. Gallagher, and H. Jenkins, SGS742: the first GABAB receptor antagonist in clinical trials, Biochemical Pharmacology, vol.68, issue.8, pp.1479-1487, 2004.
DOI : 10.1016/j.bcp.2004.07.030

G. Gachelin, De l'animal expérimental au modèle en recherche biomédicale -Revue philosophique, pp.319-326, 2008.

T. Gallarda and H. Lôo, M??mantine (Ebixa??) : une nouvelle strat??gie th??rapeutique dans le traitement des formes mod??r??ment s??v??res ?? s??v??res de la maladie d???Alzheimer, L'Enc??phale, vol.30, issue.1, pp.69-79, 2004.
DOI : 10.1016/S0013-7006(04)95418-8

S. Gauthier and . Traitement-de-la-maladie-d, Alzheimer : aspects méthodologiques généraux -Revue Neurologique, pp.261-264, 2004.

S. Gauthier, Clinical diagnostic and management of Alzheimer's disease (3ème edition) -City, 2007.

M. Gearing, G. Rebeck, and B. Hyman, Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease., Proceedings of the National Academy of Sciences, pp.9382-986, 1994.
DOI : 10.1073/pnas.91.20.9382

A. Ghosh, M. Brindisi, and J. Tang, Developing ??-secretase inhibitors for treatment of Alzheimer???s disease, Journal of Neurochemistry, vol.20, pp.71-83, 2012.
DOI : 10.1016/j.bmcl.2010.01.005

C. Gilles, S. Ertlé, and J. Macher, -Les modèles pharmacologiques dans la recherche sur la maladie d'Alzheimer -Annales Médico-psychologiques, revue psychiatrique, pp.54-62, 2001.
DOI : 10.1016/s0003-4487(00)00011-1

S. Gilman and M. Koller, Clinical effects of A?? immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, issue.9, pp.1553-1562, 2005.
DOI : 10.1212/01.WNL.0000159740.16984.3C

J. Girard and A. Canestri, -La maladie d'Alzheimer -www.sante.gouv.fr, 2000.

A. Gladkevich, F. Bosker, and J. Korf, Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders: Therapeutic potential or a mirage? -Progress in neuropsychopharmacology & biological psychiatry, pp.311347-1355, 2007.

A. Goate, -Segregation of missense mutation in the amyloide precursor protein gene with familial Alzheimer's disease ? Nature, p.7046, 1991.

J. Greenwood, SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics, Journal of Neuroimmunology, vol.71, issue.1-2, pp.51-63, 1996.
DOI : 10.1016/S0165-5728(96)00130-0

H. Grillon, Alzheimer : la stimulation sensorielle comme thérapie -Principes de santé - Thérapies, 2011.

M. Grundman, M. Farlow, and G. Peavy, A Phase I Study of AIT-082 in Healthy Elderly Volunteers, Journal of Molecular Neuroscience, vol.18, issue.3, pp.283-93, 2002.
DOI : 10.1385/JMN:18:3:283

H. Hampel, Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives, Nature Reviews Drug Discovery, vol.61, issue.7, pp.560-74, 2010.
DOI : 10.1038/jcbfm.1988.104

H. Hampel, G. Wilcock, and S. Andrieu, Diseases Biomarkers for Alzheimer's disease therapeutic trials -Progress in Neurobiology, pp.579-593, 2011.

L. Han, M. Cole, F. Bellavance, J. Mccusker, and F. Primeau, Tracking Cognitive Decline in Alzheimers Disease Using the Mini-Mental State Examination: A Meta-Analysis, International Psychogeriatrics, vol.12, issue.2, pp.231-278, 2000.
DOI : 10.1017/S1041610200006359

D. Hannequin, D. Campion, and A. Brice, Génétique de la maladie d'Alzheimer -La Revue de Médecine Interne, pp.545-550, 1996.

S. Hebert, Analyse structurale et fonctionnelle de la préséniline I humaine : implications dans la maladie d'Alzheimer -Thèse de Sciences, 2003.

D. Holtzman, J. Morris, and A. Goate, -Alzheimer's Disease: The Challenge of the Second Century -Science Translational Medicine, p.77, 2011.

M. Hong, D. Chen, P. Klein, and V. Lee, Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3, Journal of Biological Chemistry, vol.270, issue.40, pp.25326-25358, 1997.
DOI : 10.1083/jcb.98.3.847

I. Hussain, J. Hawkins, and D. Harrison, Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases ?-cleavage of amyloid precursor protein and amyloid-? production in vivo, Journal of Neurochemistry, vol.53, issue.3, pp.802-811, 2007.
DOI : 10.1358/dof.2006.031.01.957326

. Inserm-maladie-d, Alzheimer : Enjeux scientifiques, médicaux et sociétaux, Les éditions Inserm, 2007.

B. In-t-'veld and A. Ruitenberg, Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease, New England Journal of Medicine, vol.345, issue.21, pp.1515-1521, 2001.
DOI : 10.1056/NEJMoa010178

C. Jack and M. Shiung, Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD, Neurology, vol.62, issue.4, pp.591-600, 2004.
DOI : 10.1212/01.WNL.0000110315.26026.EF

C. Jack, D. Knopman, and W. Jagust, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade -Lancet Neurologie, pp.119-147, 2010.

K. Jin, V. Galvan, and L. Xie, Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice, Proceedings of the National Academy of Sciences, vol.55, issue.3, pp.13363-13370, 2004.
DOI : 10.1002/ana.10853

R. Katchadourian, Maladie d'Alzheimer ? Un coût très élevé pour les familles

R. Kayed and E. Head, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis ? Science, pp.486-495, 2003.

I. Khlistunova, J. Biernat, and Y. Wang, Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy, Journal of Biological Chemistry, vol.1739, issue.2, pp.1205-1219, 2006.
DOI : 10.1016/j.bbadis.2004.06.017

W. Klunk, B. Lopresti, and M. Ikonomovic, Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-?? in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain, Journal of Neuroscience, vol.25, issue.46, pp.10598-10606, 2005.
DOI : 10.1523/JNEUROSCI.2990-05.2005

E. Kolibas, V. Korinkova, V. Novotny, K. Vajdickova, and D. Hunakova, ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)--validation of the Slovak version, Bratislava Medical Journal, vol.101, issue.11, pp.598-602, 2000.

L. Kuller, -Statins and dementia, Current Atherosclerosis Reports, pp.154-161, 2007.

S. Kummar, R. Kinders, and L. Rubinstein, Compressing drug development timelines in oncology using phase « 0 » trials -Nature Reviews Cancer, pp.131-140, 2007.

E. Labis and F. Zakardjian, -Memantine Une nouvelle option thérapeutique pour combattre la maladie d'Alzheimer

F. M. Laferla and K. Green, -Animal Models of Alzheimer Disease -Cold Spring Harbor Perspectives in Medicine, 2012.

J. Lalonde and A. Chaudhuri, -Task-dependent transfer of perceptual to memory representations during delayed spatial frequency discrimination -Vision Research, pp.1759-1769, 2002.

J. Lambert and P. Amouyel, -Genetics of Alzheimer's disease: new evidences for an old hypothesis? - Current Opinion in, Genetics & Development, vol.21, issue.3, pp.295-301, 2011.

B. Laurijssens, F. Aujard, and A. Rahman, -Translational pharmacology Animal models of Alzheimer's disease and drug development -Drug Discovery Today: Technologies, pp.319-327, 2013.

. Leem-maladie-d, Alzheimer : Comment les industriels du médicament se mobilisent, 2011.

M. Leon, A. Convit, and A. George, In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Diseasea, Annals of the New York Academy of Sciences, vol.345, issue.1, pp.1-13, 1996.
DOI : 10.1016/S0140-6736(95)90265-1

E. Levy-lahad, -A familial Alzheimer locus on chromosome 1 ? Science, pp.970-973, 1995.

. Ligue-européenne-contre-la-maladie, Alzheimer (LECMA)-Cout http

J. Lindsay, D. Laurin, and R. Verreault, Risk Factors for Alzheimer's Disease: A Prospective Analysis from the Canadian Study of Health and Aging, American Journal of Epidemiology, vol.156, issue.5, pp.445-53, 2002.
DOI : 10.1093/aje/kwf074

C. Link, Invertebrate models of Alzheimer's disease, Genes, Brain and Behavior, vol.293, issue.3, pp.147-156, 2005.
DOI : 10.1038/35024009

P. Louzada, P. Lima, A. Mendonca-silva, and D. , Taurine prevents the neurotoxicity of ??-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer???s disease and other neurological disorders, The FASEB Journal, vol.18, issue.3, pp.511-519, 2004.
DOI : 10.1176/ajp.149.2.251

T. Lu, Y. Pan, and S. Kao, Gene regulation and DNA damage in the ageing human brain ? Nature, pp.883-91, 2004.

O. Lundbeck, Lundbeck and Otsuka initiate phase III clinical trials on Lu AE58054 as a new addon treatment for Alzheimer's disease -Corporate release 153, 2013.

C. Lyketsos, M. Steinberg, and J. Tschanz, Mental and Behavioral Disturbances in Dementia: Findings From the Cache County Study on Memory in Aging, American Journal of Psychiatry, vol.157, issue.5, pp.708-722, 2000.
DOI : 10.1176/appi.ajp.157.5.708

C. Malaplate-armand, C. Desbene, T. Pillot, and J. L. Olivier, -Diagnostic biologique de la maladie d'Alzheimer : avancées, limites et perspectives -Revue Neurologique, pp.6-7, 2009.
DOI : 10.1016/j.neurol.2008.10.015

K. Maurer, S. Volk, and H. Gerbaldo, -Des archives retrouvées par hasard révèlent les symptômes de la malade Auguste d. première patiente du docteur Alzheimer -La recherche, pp.58-60, 1997.

A. Mc-caddon and C. Kelly, Deficiency, Age and Ageing, vol.23, issue.4, pp.334-341, 1994.
DOI : 10.1093/ageing/23.4.334

M. Donald, M. Overmier, and B. , -Present Imperfect: A Critical Review of Animal Models of the Mnemonic Impairments in Alzheimer's Disease, Neuroscience & Biobehavioral Reviews, vol.22, issue.1, pp.99-120, 1997.

G. Miller and . Stopping, Alzheimer's Before It Starts ? Science, pp.790-792, 2012.

V. Moceri, W. Kukull, and I. Emanuel, Earlylife risk factors and the development of Alzheimer's disease ? Neurology, pp.415-435, 2000.

D. Morgan, D. Diamond, and P. Gottschall, A? peptide vaccination prevents memory loss in an animal model of Alzheimer's disease ?Nature, pp.982-985, 2000.

S. Moriguchi, N. Shioda, and F. Han, Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation, Hippocampus, vol.93, issue.9, pp.844-54, 2009.
DOI : 10.1212/WNL.46.2.420

K. Mullane and M. Williams, Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis???but what lies beyond?, Biochemical Pharmacology, vol.85, issue.3, pp.289-305, 2013.
DOI : 10.1016/j.bcp.2012.11.014

R. Mulnard, C. Cotman, and C. Kawas, Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease, JAMA, vol.283, issue.8, pp.1007-1022, 2000.
DOI : 10.1001/jama.283.8.1007

L. Ngatcha-ribert, Alzheimer : la construction sociale d'une maladie -Dunod, 2012.
DOI : 10.3917/dunod.ngatc.2012.01

M. Noh, S. Koh, and Y. Kim, Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-??-induced neuronal cell death, Journal of Neurochemistry, vol.67, issue.5, pp.1116-1141, 2009.
DOI : 10.1016/S0002-9440(10)63465-7

A. Nordberg, Amyloid imaging in Alzheimer's disease -Current Opinion in Neurology, pp.398-402, 2007.

F. Nourhashémi, P. Ousset, and S. Guyonnet, Maladie d'Alzheimer: De la pathogénie vers des mesures préventives ? -La Revue de Médecine Interne, pp.524-532, 2000.

F. Nourhashémi, Actualités et perspectives thérapeutiques de la maladie d'Alzheimer -La Revue de Médecine Interne, pp.585-587, 2006.

S. Oddo, A. Caccamo, and J. Shepherd, Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles, Neuron, vol.39, issue.3, pp.409-430, 2003.
DOI : 10.1016/S0896-6273(03)00434-3

S. Oddo, L. Billings, and J. Kesslak, Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome ? Neuron, pp.321-353, 2004.

H. Ollat, Alzheimer et son diagnostic prédémentiel -Neuropsychiatrie : Tendances et, Débats, vol.35, pp.33-42, 2008.

M. Pangalos, L. Schechter, and O. Hurko, Drug development for CNS disorders: strategies for balancing risk and reducing attrition -Nature Reviews Drug Discovery, pp.521-553, 2007.

A. Paucot, Le dictionnaire impertinent du Futur: Se divertir en découvrant l'avenir et le présent - M21 Editions, 2008.

M. Perez and . Santé, un bon niveau d'études protège contre Alzheimer, 2012.

C. Phiel, C. Wilson, V. Lee, and P. Klein, GSK-3?? regulates production of Alzheimer's disease amyloid-?? peptides, Nature, vol.5, issue.6938, pp.435-444, 2003.
DOI : 10.1038/nn898

A. Piau, F. Nourhashemi, and B. Vellas, -Iatrogénie et maladie d'Alzheimer -La Revue de Médecine Interne, pp.302-306, 2009.

J. Poirier, Le système nerveux -www.arsep.org -consulté le 05, 2012.

M. Proult, -Les connaissances du pharmacien sur la maladie d'Alzheimer -Actualités pharmaceutiques, pp.9-20, 2009.
DOI : 10.1016/s0515-3700(09)70010-2

H. Querfurth and F. M. Laferla, Alzheimer's Disease, New England Journal of Medicine, vol.362, issue.4, pp.329-344, 2010.
DOI : 10.1056/NEJMra0909142

H. Ramaroson, C. Helmer, P. Barberger-gateau, L. Letenneur, and J. Dartigues, -Prevalence of dementia and Alzheimer's disease among subjects aged 75 years or over: updated results of the PAQUID cohort, Revue neurologique, vol.159, pp.405-411, 2003.

T. Rapp, S. Andrieu, L. Molinier, A. Grand, C. Cantet et al., -Exploring the Relationship between Alzheimer's Disease Severity and Longitudinal -Costs Value in Health, pp.412-419, 2012.

E. Reiman, J. Langbaum, and A. Fleisher, The Alzheimer's Prevention Initiative, Alzheimer's & Dementia, vol.8, issue.4, pp.321-330, 2011.
DOI : 10.1016/j.jalz.2012.05.1136

J. Rich, D. Rasmusson, and M. Folstein, Nonsteroidal anti-inflammatory drugs in Alzheimer's disease ? Neurology, pp.51-56, 1995.

D. Rodríguez-arias, -Recherche biomédicale et pratiques cliniques Histoire d'une distinction problématique ? Inserm, 2004.

M. Sabbagh, S. Richardson, and N. Relkin, Disease-modifying approaches to Alzheimer???s disease: Challenges and opportunities???Lessons from donepezil therapy, Alzheimer's & Dementia, vol.4, issue.1, pp.109-127, 2008.
DOI : 10.1016/j.jalz.2007.11.013

M. Sabbagh, Drug development for Alzheimer's disease: Where are we now and where are we headed?, The American Journal of Geriatric Pharmacotherapy, vol.7, issue.3, pp.167-85, 2009.
DOI : 10.1016/j.amjopharm.2009.06.003

J. Sabbagh, J. Kinney, and J. Cummings, -Alzheimer's disease biomarkers: correspondence between human studies and animal models -Neurobiology of Disease, pp.116-146, 2013.

S. Salloway and R. Sperling, Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein E ?4 carriers (study 302) and non-carriers (Study 301). - Clinical Outcomes ? Clinical Trials in Alzheimer's Disease ? 10, 2012.

O. Samaoli and . Vieillesse, démence et immigration: Pour une prise en charge adaptée des personnes âgées migrantes en France, Danemark et au Royaume-Uni -L'Harmattan, 2000.

R. Sandbrink, T. Hartmann, C. Masters, and K. Beyreuther, -Genes contributing to Alzheimer's disease - Molecular Psychiatry, pp.27-40, 1996.

T. Sang and G. Jackson, -Drosophila models of neurodegenerative disease ? NeuroRx, pp.438-446, 2005.

M. Sano, K. Bell, and D. Galasko, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease ? Neurology, pp.556-63, 2011.

D. Schenk, R. Barbour, and W. Dunn, Immunization with amyloid-? attenuates Alzheimer-diseaselike pathology in the PDAPP mouse ? Nature, pp.173-177, 1999.

S. Schroeter, K. Khan, and R. Barbour, Immunotherapy Reduces Vascular Amyloid-?? in PDAPP Mice, Journal of Neuroscience, vol.28, issue.27, pp.6787-93, 2008.
DOI : 10.1523/JNEUROSCI.2377-07.2008

D. Scimeca and M. Tétau, Votre santé par les plantes: Le guide phyto utile pour toute la famille -Alpen Editions, 2005.

C. Scorer, Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease -Drug Discovery Today, pp.1207-1219, 2001.

J. Selmès, Alzheimer : Accompagnez votre proche au quotidien -John Libbey Eurotext, 2011.

G. Shankar, M. Leissring, and A. Adame, Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life -Neurobiology of Disease, pp.293-302, 2009.

L. Sherwood, -Physiologie humaine -Edition de Boeck, 2006.

O. Shif, K. Gillette, and C. Damkaoutis, Effects of Ginkgo biloba administered after spatial learning on water maze and radial arm maze performance in young adult rats, Pharmacology Biochemistry and Behavior, vol.84, issue.1, pp.17-25, 2006.
DOI : 10.1016/j.pbb.2006.04.003

M. Slegtenhorst, J. Lewis, and M. Hutton, The molecular genetics of the tauopathies, Experimental Gerontology, vol.35, issue.4, pp.461-471, 2000.
DOI : 10.1016/S0531-5565(00)00114-5

R. Sperling, M. Donohue, and P. Aisen, -The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease. -Alzheimer's & Dementia, pp.425-451, 2012.

M. Spillantini and M. Goedert, Tau protein pathology in neurodegenerative diseases -Trends Neuroscience, pp.428-461, 1998.

L. Spinney, Update on Elan vaccine for Alzheimer's disease -The Lancet Neurology, p.5, 2004.

T. Spires and B. Hyman, Transgenic models of Alzheimer???s disease: Learning from animals, NeuroRX, vol.389, issue.3, pp.423-437, 2005.
DOI : 10.1038/39321

L. Squire, E. Kandel, and . Mémoire, De l'esprit aux molécules -De Boeck Supérieur, 2002.

S. George-hyslop, P. Petit, and A. , Molecular biology and genetics of Alzheimer's disease, Comptes Rendus Biologies, vol.328, issue.2, pp.119-130, 2005.
DOI : 10.1016/j.crvi.2004.10.013

D. Stora, Pharmacie et surveillance infirmière, 2008.

F. Takata, S. Dohgu, and A. Yamauchi, In Vitro Blood-Brain Barrier Models Using Brain Capillary Endothelial Cells Isolated from Neonatal and Adult Rats Retain Age-Related Barrier Properties, PLoS ONE, vol.63, issue.1, 2013.
DOI : 10.1371/journal.pone.0055166.g005

S. Tayebati, Animal models of cognitive dysfunction -Mechanisms of Ageing and Development, pp.100-108, 2006.

A. Terry, -Methods of Behavior Analysis in Neuroscience, 2009.

H. Tohgi, T. Abe, and K. Hashiguchi, Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia -Neuroscience Letters, pp.139-142, 1994.

D. Tritsch and D. Chesnoy-marchais, Anne Feltz A. -Physiologie du neurone, 1999.

J. Trojanowski and H. Hampel, Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention, Progress in Neurobiology, vol.95, issue.4, pp.491-496, 2011.
DOI : 10.1016/j.pneurobio.2011.07.004

A. Valleron and . Humaine, Conditions de son développement en France, et rôle des mathématiques, 2006.

V. Vanhooren and C. Libert, The mouse as a model organism in aging research: Usefulness, pitfalls and possibilities, Ageing Research Reviews, vol.12, issue.1, pp.8-21, 2003.
DOI : 10.1016/j.arr.2012.03.010

J. Van-horssen, P. Wesseling, and L. Van-den-heuvel, Heparan sulphate proteoglycans in Alzheimer's disease and amyloid???related disorders, The Lancet Neurology, vol.2, issue.8, pp.482-92, 2003.
DOI : 10.1016/S1474-4422(03)00484-8

V. Marum and R. , Current and future therapy in Alzheimer's disease -Fundamental & Clinical Pharmacology, pp.265-274, 2008.

B. Vellas, M. Carrillo, and C. Sampaio, Designing drug trials for Alzheimer???s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force, Alzheimer's & Dementia, vol.9, issue.4, pp.438-482, 2013.
DOI : 10.1016/j.jalz.2013.03.007

T. Vogel, A. Benetos, and R. Verreault, Facteurs de risque de la maladie d'Alzheimer: vers une prévention? -La Presse Médicale, pp.1309-1316, 2006.
DOI : 10.1016/s0755-4982(06)74810-2

D. Walsh, I. Klyubin, and J. Fadeeva, Naturally secreted oligomers of amyloid ?? protein potently inhibit hippocampal long-term potentiation in vivo, Nature, vol.36, issue.6880, pp.535-539, 2002.
DOI : 10.1021/jm00054a014

M. A. Wheeler, D. T. Stuss, and E. Tulving, Toward a theory of episodic memory: The frontal lobes and autonoetic consciousness., Psychological Bulletin, vol.121, issue.3, pp.331-354, 1997.
DOI : 10.1037/0033-2909.121.3.331

J. Wiltfang, P. Lewczuk, and P. Riederer, Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia, The World Journal of Biological Psychiatry, vol.70, issue.2, pp.69-84, 2005.
DOI : 10.1136/jnnp.70.2.229

A. Wimo and M. Prince, Alzheimer's Disease International. The Global Economic Impact of Dementia - World Alzheimer Report, 2010.

A. Wimo, L. Jönsson, and A. Gustavsson, The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project, International Journal of Geriatric Psychiatry, vol.20, issue.(Suppl 1), pp.825-832, 2011.
DOI : 10.1002/gps.1332

T. Wisniewski and A. Boutajangout, -Vaccination as a therapeutic approach to Alzheimer'Disease - Journal of medicine, pp.17-31, 2010.

D. Woodruff-pak and J. Trojanowski, -The older rabbit as an animal model: implications for Alzheimer's disease -Neurobiology of Aging, pp.283-290, 1996.

C. Wu, J. Scott, and J. Shea, Binding of Congo Red to Amyloid Protofibrils of the Alzheimer A??9???40 Peptide Probed by Molecular Dynamics Simulations, Biophysical Journal, vol.103, issue.3, pp.550-557, 2012.
DOI : 10.1016/j.bpj.2012.07.008

K. Yamada and T. Nabeshima, Animal models of Alzheimer's disease and evaluation of anti-dementia drugs -Pharmacology & Therapeutics, pp.93-113, 2000.